Form 4: Immunome Director Isaac Barchas Receives Stock Options

Director Isaac Barchas was granted 9,897 stock options in Immunome, Inc. to be held for the benefit of Arsenal Bridge Ventures.

Summary

• Director Isaac Barchas received a grant of 9,897 stock options for Immunome, Inc. (IMNM) on June 10, 2026.
• The options have an exercise price of $18.16 per share.
• The options vest in four equal quarterly installments over one year, starting June 10, 2026.
• The reporting person disclaims beneficial ownership, as the securities are held for the benefit of Arsenal Bridge Ventures.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Alignment of director interests with long-term company performance through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Vesting is subject to the director's continuous service with the company.

Future Outlook

The options vest quarterly over one year, contingent upon the director's continued service to the company.

Management Comments

• Mr. Barchas has agreed to receive and hold for the benefit of Arsenal Bridge Ventures any securities granted to him for his service as a director on the Company's board of directors.
• Mr. Barchas disclaims beneficial ownership of, and all right, title and interest in, the reported securities.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practice in the biotechnology sector to ensure board members are incentivized to drive shareholder value.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard compensation packages for small-cap biotechnology firms.
• The one-year vesting schedule is relatively aggressive compared to the typical three-to-four-year vesting schedules seen in larger cap companies.

Related Party Transactions

• The director holds the granted securities for the benefit of Arsenal Bridge Ventures.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new options.

Next Steps

• Quarterly vesting of options beginning September 2026.

Key Dates

Keywords

Immunome, IMNM, Form 4, Director Compensation, Stock Options, Insider Trading